These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 35871128)

  • 1. Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.
    Breslau RM; Cohen JT; Ollendorf DA; Neumann PJ
    Pharmacoecon Open; 2022 Nov; 6(6):893-895. PubMed ID: 35871128
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 3. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports.
    Snider JT; Sussell J; Tebeka MG; Gonzalez A; Cohen JT; Neumann P
    Value Health; 2019 Mar; 22(3):332-339. PubMed ID: 30832971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Assessment in Cystic Fibrosis: ICER's Rejection of the Axioms of Fundamental Measurement.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.
    Gerlach JA; Snow B; Prioli KM; Vertsman R; Patterson J; Pizzi LT
    Am Health Drug Benefits; 2020 Sep; 13(4):136-142. PubMed ID: 33343812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 9. Worldwide HTA access to ICER's cost-effectiveness models.
    PharmacoEcon Outcomes News; 2020; 864(1):3. PubMed ID: 33082704
    [No Abstract]   [Full Text] [Related]  

  • 10. ICER evokes Dusp1-p38 pathway enhancing chemotherapy sensitivity in myeloid leukemia.
    Pigazzi M; Manara E; Beghin A; Baron E; Tregnago C; Basso G
    Clin Cancer Res; 2011 Feb; 17(4):742-52. PubMed ID: 21325296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Levonorgestrel-releasing Intrauterine System (LNG-IUS) against Laparoscopic Assisted Supracervical Hysterectomy (LASH) for menorrhagia treatment: An economic evaluation.
    Laughton M; Patel NC; Dawoodbhoy FM; El-Ghrably S; Mahmud S
    J Gynecol Obstet Hum Reprod; 2021 Dec; 50(10):102229. PubMed ID: 34520876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of repression of the inhibin alpha-subunit gene by inducible 3',5'-cyclic adenosine monophosphate early repressor.
    Burkart AD; Mukherjee A; Mayo KE
    Mol Endocrinol; 2006 Mar; 20(3):584-97. PubMed ID: 16269517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcriptional repressor ICER binds to multiple loci throughout the genome.
    Muñiz LC; Molina CA
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1462-5. PubMed ID: 27590584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
    Synnott PG; Bloudek LM; Sharaf R; Carlson JJ; Pearson SD
    J Manag Care Spec Pharm; 2020 Mar; 26(3):236-239. PubMed ID: 32105176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICER's second update to pricing models of remdesivir for COVID-19.
    PharmacoEcon Outcomes News; 2020; 867(1):2. PubMed ID: 33262564
    [No Abstract]   [Full Text] [Related]  

  • 17. ICER's timelines for assessments extended due to COVID-19.
    PharmacoEcon Outcomes News; 2020; 850(1):1. PubMed ID: 32288506
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility and cost-effectiveness of individual placement support and cognitive remediation in people with severe mental illness: Results from a randomized clinical trial.
    Christensen TN; Kruse M; Hellström L; Eplov LF
    Eur Psychiatry; 2020 Dec; 64(1):e3. PubMed ID: 33342450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
    Cherla A; Renwick M; Jha A; Mossialos E
    EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.